1,066
Views
14
CrossRef citations to date
0
Altmetric
Clinical Research

Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health

ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon
Pages 152-157 | Received 14 Apr 2020, Accepted 05 Jun 2020, Published online: 18 Jun 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Kevin Baumgartner, Michelle Doering and & Michael E. Mullins. (2022) Dexmedetomidine in the treatment of toxicologic conditions: a systematic review and review of the toxicology investigators consortium database. Clinical Toxicology 60:12, pages 1356-1375.
Read now
William Rushton & Jessica Rivera. (2021) Tianeptine: a new frontier in surveillance and understanding through social media. The American Journal of Drug and Alcohol Abuse 47:4, pages 411-413.
Read now

Articles from other publishers (12)

Henrik Galust, Justin A. Seltzer, Jeremy R. Hardin, Nathan A. Friedman & Alicia Minns. (2023) “Tianeptine abuse via novel, extended-release, star-shaped, drug delivery device”. Toxicology Reports 11, pages 162-164.
Crossref
Jennifer L. Hargett, Presly F. Lowry & Keyshawnna N. Lee. (2023) Nursing Implications for Tianeptine Use and Misuse. Journal of Addictions Nursing 34:2, pages 158-161.
Crossref
Marija Markovic & Dania Niwash. (2022) Treatment of concurrent etizolam and tianeptine withdrawal following accidental overdose. Mental Health Clinician 12:6, pages 356-359.
Crossref
Magnus A. B. Axelsson, Hanna Lövgren, Robert Kronstrand, Henrik Green & Moa Andresen Bergström. (2022) Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis. Basic & Clinical Pharmacology & Toxicology 131:5, pages 420-434.
Crossref
Laura Szczesniak & Ross Sullivan. (2022) Microdose Induction of Buprenorphine in a Patient Using Tianeptine. Journal of Addiction Medicine 16:6, pages 736-738.
Crossref
Luke A. Jelen, James M. Stone, Allan H. Young & Mitul A. Mehta. (2022) The opioid system in depression. Neuroscience & Biobehavioral Reviews 140, pages 104800.
Crossref
Amanda L A Mohr, Barry K Logan, Melissa F Fogarty, Alex J Krotulski, Donna M Papsun, Sherri L Kacinko, Marilyn A Huestis & Jeri D Ropero-Miller. (2022) Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review. Journal of Analytical Toxicology 46:6, pages e116-e185.
Crossref
T. R. Baird, H. I. Akbarali, W. L. Dewey, H. Elder, M. Kang, S. A. Marsh, M. R. Peace, J. L. Poklis, E. J. Santos & S. S. Negus. (2022) Opioid-like adverse effects of tianeptine in male rats and mice. Psychopharmacology 239:7, pages 2187-2199.
Crossref
Avery E. Michienzi & Heather A. Borek. (2022) Emerging Agents of Substance Use/Misuse. Emergency Medicine Clinics of North America 40:2, pages 265-281.
Crossref
Robinson Gravier Dumonceau, Thomas Soeiro, Clémence Lacroix, Adeline Giocanti, Élisabeth Frauger, Salim Mezaache & Joëlle Micallef. (2021) Antidepressants abuse in subjects with opioid use disorders: A 10‐year study in the French OPPIDUM program. Fundamental & Clinical Pharmacology 36:2, pages 436-442.
Crossref
. (2021) Multiple drugs. Reactions Weekly 1845:1, pages 282-282.
Crossref
Marthe M. Vandeputte, Annelies Cannaert & Christophe P. Stove. (2020) In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Archives of Toxicology 94:11, pages 3819-3830.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.